AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo

Evonik opens new medical device center in Shanghai

The company’s largest center for medical device applications, serving the entire Asian market

Bayer submits EU application for Gadoquatrane MRI contrast agent

It is intended for contrast enhancement in MRI scans

Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products

Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content

CARE Hospitals, Hitech City introduces AI-powered robotic surgery system

The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution

AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment

Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments

Veerhealth Care enters into contract manufacturing agreement

Commercial production is expected to begin soon

Suraksha Diagnostic unveils Eastern India's largest genomics lab

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone

European Commission fines Alchem for participating in API cartel

The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle